Monte Rosa Therapeutics (NASDAQ:GLUE) COO Sells 2,175 Shares

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,175 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $20.00, for a total value of $43,500.00. Following the completion of the transaction, the chief operating officer owned 62,371 shares in the company, valued at $1,247,420. This represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, June 17th, Jennifer Champoux sold 2,176 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $19.00, for a total value of $41,344.00.
• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $43,500.00.

Monte Rosa Therapeutics Price Performance

Shares of Monte Rosa Therapeutics stock traded up $0.81 during trading on Thursday, hitting $21.66. 1,768,259 shares of the company were exchanged, compared to its average volume of 1,328,242. The firm has a market capitalization of $1.83 billion, a P/E ratio of -14.64 and a beta of 1.60. The firm’s fifty day moving average price is $18.79 and its 200 day moving average price is $18.58. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million during the quarter, compared to analyst estimates of $10.95 million. As a group, equities research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Monte Rosa Therapeutics by 8.6% in the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after purchasing an additional 257,547 shares during the period. Massachusetts Financial Services Co. MA bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth about $778,000. Strs Ohio bought a new position in shares of Monte Rosa Therapeutics during the fourth quarter worth about $566,000. CWM LLC raised its position in Monte Rosa Therapeutics by 13.6% in the 4th quarter. CWM LLC now owns 29,444 shares of the company’s stock valued at $462,000 after buying an additional 3,536 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares in the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Wall Street Zen cut Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Guggenheim cut their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.